Floatz logo

hu6

Heart Failure With Preserved Ejection Fraction

Rivus Pharmaceuticals, Inc.Phase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

17 Active assets in the Heart Failure With Preserved Ejection Fraction cohort.

Asset / SponsorPhaseRating
Semaglutide
Mayo Clinic
Phase 4BBB
Metformin
Sara ElAdawy
Phase 4BBB
Tirzepatide
Yunlong Wang
Phase 4BBB
Liraglutide
Leiden University Medical Center
Phase 4BBB
BENZBROMARONE
National Defense Medical Center, Taiwan
Phase 4BB

View all 23 →

Same molecule, other indications

hu6 is also rated in:

metabolic dysfunction-associated steatohepatitisDormant
BB
Indicative ·
64 / 100
View asset →
obesity disorderDormant
B
Indicative ·
60 / 100
View asset →
fatty liver diseaseDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →